Progression-Free Survival, Overall Survival Similar Between Olaparib, Chemotherapy
The CLIO trial evaluated olaparib single-agent therapy versus standard-of-care chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer.
The rates of progression-free survival (PFS) and overall survival (OS) were similar between olaparib monotherapy and chemotherapy in recurrent germline BRCA wildtype platinum-sensitive epithelial ovarian cancer, according to a study presented via the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer.
The CLIO trial evaluated olaparib single-agent therapy versus standard-of-care chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer. Patients who were eligible had measurable germline BRCA wildtype platinum-sensitive recurrent epithelial ovarian cancer and experienced a relapse ≥6 months after platinum-based chemotherapy and had less than 1 prior line of chemotherapy. The patients were randomized 2 to 1 to olaparib monotherapy or physician’s choice chemotherapy.
The response was evaluated according to RECIST version 1.1. Prior bevacizumab was allowed and disease control rate was defined as response or stable disease at 12 weeks.
A total of 60 patients were randomized and baseline characteristics were not significantly different between both arms. The objective response rate was 40% for olaparib and 85% for chemotherapy.
PFS was similar in both arms for olaparib and chemotherapy, respectively, as was OS. Adverse events in the olaparib and chemotherapy arms did not reveal any unexpected events, as somatic BRCA testing is ongoing.
Loverix L, Vanderstichele A, Olbrecht S, et al. Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer. SGO 2020. https://sgo.confex.com/sgo/2020/meetingapp.cgi/Paper/16863. Presented March 29, 2020. Accessed April 7, 2020.